Evidence map›Paper›PMID 41688468›Full record

ArticleNPJ breast cancer2026

Androgen receptor expression and immune characteristics of HER2-low metastatic triple-negative breast cancer.

Paolo Tarantino, Jaeyoon Cha, Busem Binboga Kurt, Xiangying Chu, Bojana Jovanović, Andrew Zhou, Melissa Hughes, Douglas Russo, Molly DiLullo, Eileen Wrabel and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ breast cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Paolo Tarantino *Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Paolo_Tarantino@dfci.harvard.edu.
Jaeyoon Cha *Harvard Medical School, Boston, MA, USA.
Busem Binboga KurtDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
Xiangying ChuDepartment of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA.
Bojana JovanovićDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Andrew ZhouHarvard Medical School, Boston, MA, USA.
Melissa HughesDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Douglas RussoDepartment of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA.
Molly DiLulloDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Eileen WrabelDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Rinath JeselsohnDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Nancy U LinDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Jamie CarterBreast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
Yisang Serenity ChenBreast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
Tianyu LiDepartment of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA.
Nabihah TayobHarvard Medical School, Boston, MA, USA.
Elizabeth A MittendorfBreast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
Stuart J SchnittBreast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
Shom GoelDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Sara M TolaneyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

HER2-low expression is associated with hormone receptor (HR) expression in HR-positive breast cancer. We aimed to evaluate its association with androgen receptor (AR) among 196 patients with metastatic triple-negative breast cancer (mTNBC). Central determination of AR showed significant enrichment in HER2-low compared with HER2-0 mTNBC (mean: 33.7% vs. 21.4%, p = 0.038), whereas no significant immunological differences were observed. HER2-low/AR-positive patients trended towards longer overall survival, highlighting the potential relevance of these biomarkers.

Identifiers

PMID41688468
PMCPMC13013833

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.